Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

The resolution of shortages for tirzepatide and other GLP-1 medications, such as semaglutide, signals a potential shift toward increased FDA enforcement as the agency works to align industry ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

From 2020 to 2024, availability increased, especially in FFS; GLP-1 RA availability in MCOs plateaued at less than 60 percent since 2022. Tirzepatide was almost totally restricted.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes.

In 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and postoperative period experienced significantly greater weight loss -- a 33% ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, according to a study being presented by a private weight-loss company Monday ...

Health How Making GLP-1s Available Over the Counter Can Unlock Their Full Potential Drugs like Ozempic might not only address obesity but also alcoholism, smoking, and drug addiction.

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...